C. botulinum neurotoxins are acutely toxic materials and act by inhibiting release of the neurotransmitter acetylcholine. The specific nature of this inhibition is discussed and the preparation and purification of Type A toxin specifically for clinical use is described.
There have been few drugs whose mode and site of action and detailed pharmacology have been so well understood prior to their clinical application as Type A botulinum toxin. Indeed, the nature of this family of neu roparalytic agents as the most acutely potent microbial toxins and the cause of the food borne illness botulism has made regulatory authorities particularly cautious in approving their clinical application. Nevertheless the use of the toxin particularly to treat a variety of dystonic conditions represents a most elegant, precise and safe treatment which reflects con siderable credit on the pioneering work of Scotti who first instituted the use of the toxin for human therapy.
The therapeutic, as well as the prophylactic (vaccine) use of microbial products is, of course, well established and as well as native products, especially antibiotics, also includes bacterial asparaginases used to treat acute lymphoid and lymphoblastic leukaemia in children. 2 Increasingly we are also seeing human gene products such as insulin, growth hormone and interferons produced in micro organisms and used for human therapy. It is virtually certain that many other potent human regulatory proteins will also become available by this route.
Thus when it comes to pharmaceutical pro duction C. botulinum toxin can be viewed as one of the first of a group of high activity protein products prepared from cultures of micro-organisms and the problems and solu tions in handling such materials have general applications.
The purpose of this article is to review the nature of C. botulinum toxins and to describe the procedures involved in the production, purification and presentation of the type A toxin for clinical use.
The Nature of the Toxins Structure Complex toxins. There are eight serologically distinct toxins (A, B, Cb C 2 , D, E, F and G) produced by C. botulinum that are among the most powerful neuroparalytic agents known. The toxins so far studied all appear to occur both naturally and in in vitro culture com plexed with non-toxic proteins which may co-purify with the toxin moiety (Fig. 1) . Of these complexes the smallest, the M or medium complexes, comprise the neurotoxin moiety (ca. 150,000 daltons) associated with a similar sized non-toxic protein of undeter mined biological activity and are the only forms found for the types C3, E4.5 and P and haemagglutinin-negative strains of type D7. Types AS, B9 and haemagglutinin-positive D7 also occur as trimolecular or L (large) com plexes comprising the M complex in associ ation with a non-toxic protein having haemagglutinin activity. The L complexes (Ca, 500,000 daltons) are the largest complex states of these toxins with the exception of type A toxin which also occurs as a complex of about 900,000 daltons. This latter complex, which is thought to consist of dimers of the L complex, is the molecular size of the type A toxin in the crystalline state.
Neurotoxins. The various C. botulinum neu rotoxins, although serologically distinct, appear to be structurally very similar to each other; the purified neurotoxins having similar molecular sizes and sharing a common subunit structure (Table II) . These single chain pro genitor toxins may be cleaved by proteolytic enzymes to give biologically active dichain toxins (Fig. 2) . The dichain toxins consist of one large (heavy, H) and one small (light, L) subunit linked by at least one disulphide bridge; the H subunits are about double the molecular size of the L subunits4.6.10-19 (Table I ). The amino acid composition of several toxin types (A, B, C, D, E and F) have been evaluated I 6.18.20-22 and similarities are appar ent. In particular all have high contents of hydrophobic amino acids residues which may be relevant to the membrane binding/inter nalisation of the toxin as discussed later. The similarities in amino acid compOSItion together with their shared pharmacological action imply that, despite their lack of anti genic cross-reactivity, there may well be regions of structural homology within the neurotoxins. Neurotoxin subunits. Reduction of the disul phide link( s) between H and L subunits generally leads to a loss of toxicity and a reduction in the solubility of the toxin. The subunits of reduced neurotoxin remain associ ated by covalent forces but these can be dis sociated and solubilised by urea and subsequently separated chromatographi cally. 16 -1 8 . 23 -2 5
Purified H and L subunits of the neurotox ins are of greatly reduced specific toxicity «0.5 per cent) compared to the intact toxin; the residual toxicity probably being due to trace contamination with intact toxin.16 Sep arated n eurotoxin subunits appear to main tain their structural integrity and can be recombined into intact neurotoxin by mixing equimolar portions of each subunit, in reduc ing conditions, and slowly removing the When administered by the parent eral route the non-toxic proteins of the com plexes appear not to play a role in toxicity, indeed, the highest specific toxicities are observed with the purified neurotoxin compo nent (Table II) . For example, the purified 145,000 dalton type A neurotoxin (S-form) has a specific toxicity about 3 fold higher than that of its L complex. In contrast, the complex toxins are more toxic than purified neurotox ins when administered orally (Table II) . This difference is even more pronounced with the type B toxin where oral toxicities of the S, M and L forms are in the ratio of 112/1,600 respectively. 26 Differences in the oral tox icities of toxins from two different type B strains of C. botulinum were attributed entirely to differences in the properties of the non-toxic proteins of the respective complex toxins. The enhanced oral toxicity of the com plex toxins probably reflects the ability of the non-toxic proteins to protect the neurotoxin moiety from the hostile environment of the Not yet chracterised digestive tract prior to its uptake into the blood and lymphatic systemsY·28
Mode of Action
The botulinum neurotoxins act primarily on the peripheral cholinergic synapses where, by inhibiting the release of the neurotransmitter acetylcholine, they cause the widespread mus cular paralysis characteristic of the fatal syn drome botulism. Studies with isolated neuromuscular junction preparations show that the action of the toxin is not mediated merely by its binding to the nerve membrane; since binding is rapid, whereas paralysis has a slower onset. 30 Furthermore, in contrast to the rapid binding, stimulation of the nerve is required to induce paralysis which is tempera ture sensitive and requires the presence of calcium ions in the fluid bathing the neu romuscular junction.3H3 It is now believed that at least three steps are involved in the inhibitory action of bot ulinum toxins. Firstly, there is a binding step, whereby the toxin attaches rapidly and avidly to the presynaptic nerve membrane. Secondly, an internalisation step in which toxin crosses the presynaptic membrane and a final step, or steps, whereby toxin inhibits the release of the neurotransmitter substance, acetylcholine. Toxin binding. Selective, saturable binding of botulinum neurotoxins to presynaptic nerve membranes of both peripheral and central nerves has been shown using labelled toxin molecules. 34-36 Neurotoxin visualised with fer ritin-labelled antibody was observed to bind in discrete patches of varying size rather than uniformly over the nerve surface.36 Studies using synaptosomes from rat or mouse brain have shown that the binding of radio-labelled toxin is inhibited by an excess of unlabelled toxin, indicating that a limited number of binding sites are available.37 Two types of acceptor component appear to be involved; a small proportion of sites bind neu r otoxin with high affinity (Kd<l nM) and a larger pool of acceptor sites bind toxin with lower affinity (Kd>20 nM) (Table III) . If one assumes that each neurotoxin contains but one binding (active) site then it seems most likely that the toxin forms a 'good fit' with the high affinity sites but a 'poor fit' with the low affinity ones. Although the similar structural and phar macological properties of the various bot ulinum neurotoxin types suggest they may have similar modes of action, it would appear that the synaptosomal acceptor sites may dif fer from some toxin types. There may, indeed, be at least two groups of synaptoso mal acceptors, one recognised by the A and E toxins and one by the Type B toxin, since there is little or no competition between Types A and B or B and E for binding to synapto somes whereas Types A and E appear to com pete for the same acceptor sites. 1 4 . 3 7. 40 Similarly, binding of Type D toxin is com pletely inhibited by C I toxin, suggesting com mon acceptor components.1 8 Whether these are similar to the acceptors for either A and E or B toxins is not yet known. The role of subunits in binding to acceptors. In those botulinum neurotoxins so far studied the H subunit appears to contain the active site which binds to synaptosomal acceptor. For both A and B toxins homologous unlabelled H-subunit reduces binding of radio-labelled toxin, whereas the L chain is without effect. Similarly Type D toxin binding is inhibited by Types C, and D H subunits.
The single chain forms of B and E toxins bind to synaptosomes with similar affinities to nicked, active toxinl4.42 implying that the rela tive non-toxicity of the single chain molecule does not reflect an inability to bind to the nerve terminal but rather to some subsequent step in the toxins' action.
Direct evidence of toxin internalisation was provided by experiments using hem i diaphragms incubated with radio-labelled Type A neurotoxin. 34 Electron micro-auto radiographs showed that following binding to the nerve terminal membrane transfer of labelled toxin across the plasma membrane was evident after about 20 minutes and was maximal after 90 minutes. The translocation process which did not require the presence of Ca2+ ions nor indirect stimulation of the nerve was abolished at low temperatures or by inhibitors of energy production. The latter did not, however, prevent binding to the mem brane surface indicating that energy is required only for internalisation. From elec tron micrographs of nerve preparations in which toxin internalisation was prevented it was estimated that there were between 150-500 acceptor sites per �m2 on the nerve sur face.34 Detailed quantitation of EM auto radiographs revealed that not all bound material was internalised and that some 60 per cent remained associated with the membrane. Neurotransm itter release. Since botulinum toxins appear to inhibit neither neu rotransmitter synthesis nor storage disruption of the Ca2+ -mediated acetylcholine release mechanism seems probable. Three pos sibilities exist; toxin could inhibit Ca2+ influx during nerve stimulation or stimulate Ca2+ efflux, or it could act directly on some stage in the release mechanism itself. No hypothesis adequately accounts for all the available data although most evidence argues against bot ulinum toxin acting by inhibiting Ca2+ influx.
In the early stages of botulinum toxin poi soning of the neuromuscular junction the effects can be reversed by increasing the flow of Ca2+ into the nerve terminal.43 However, as the poisoning progresses so the ability of Ca2+ to reverse the toxic effects is diminished. It is conceivable then, that the botulinum toxin may act by reducing the sensitivity of the neu rotransmitter release mechanism to Ca2+ such that the normal intracellular Ca2+ levels are insufficient to promote release. Similar conclusions are indicated by studies with substances such as tetraethylam monium43 and 4-aminopyridine44-46 which, in prolonging the depolarisation/repolarisation cycle of the nerve, allow higher con centrations of Ca2+ to build up in the nerve terminal. In these conditions the end plate potentials of mildly botulinum-poisoned neu romuscular junction preparations can be restored to normal.
Many key aspects of the action of the bot ulinum neurotoxins still await clarification, including the appearance of minature end plate potentials shortly after the onset of poisoning and particularly the long duration of the toxic effects. One possibility is that the toxin evokes a permanent change in an enzyme, or other vital system, having a long half life. 47,79 Indeed it has been proposed that, in common with some other microbial toxins, the toxin itself may be an enzyme; the pro tracted action and high specificity of the toxin appears to support this view.
Preparation of Type A Toxin for Clinical Use
For a product to be acceptable and licensable for clinical use appropriate standards of quality, safety and efficacy must be achieved. Thus material must be reproducible in its composition and potency from batch to batch and stable during a particular period under defined and achievable storage conditions. Safety and efficacy need to be assessed both by animal experimentation and in human trials and to be verifiable on subsequent batches by the application of relevant quality control tests. All of the above requires the application of Good Manufacturing Practice (GMP) techniques. GMP builds on labora tory biochemistry and microbiology and translates a Research and Development pro cess into an effective pharmaceutical oper ation. The importance of standardising conditions for production and purification is clearly apparent given the effect of proteolytic 'nicking' on toxic activity and the further sus ceptibility of the protein toxin to inactivation by proteolytic enzymes. Culture. Cultures of C. botulinum from a veri fied seed stock are grown up and inoculated into a 30 1 fermenter operated under ana erobic conditions and toxin production and other culture parameters are monitored (Fig. 3) . When the maximum yield of toxin has been attained (2x106 mouse LDsolml) usually after 72 hours the toxin is harvested by centrifugation after acidifying the culture. In this form the toxin can be stored prior to purification. Cultures are extensively checked for toxin activitiy, identity and absence of contamination. 
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Purification. The precipitated crude toxin is re-dissolved and purified by a series of pro cedures involving ammonium sulphate pre cipitation and ion-exchange chromatography (Table IV) . During these procedures the pro cess is monitored for the absence of con tamination with extraneous micro-organisms as well as the toxicity and protein content of the extracts. Formulation and Freeze Drying. The potency of the purified toxin is assessed and an appro priate quantity of the purified toxin solution is added to a diluent containing lactose and human serum albumin. The diluent is designed to provide protection for the toxin during freeze-drying and to act as a bulking agent for the freeze dried product. Prior to freeze drying, the diluted toxin is dispensed into vials and at the completion of the drying process vials are checked for integrity, ster ility, moisture content and potency.
Clinical Use and Dosage C. botulinum toxin has now been used to treat both experimentally and routinely a range of Clearly the muscle sizes, and most critically the number of cholinergic synapses, vary con siderably among these conditions as it is clear does the dose of toxin required for effective action. It is likely that for the effective treat ment of patients and the convenience of clini cians toxin will need to be made available in a range of doses appropriate to the particular condition and even for one condition individ ual patient responses may dictate varying doses. Accordingly we decided to present the toxin which has been used for blepharospasm and strabismus treatment as a weight of active protein determined by mouse potency; the use of units of activity based on human phys iological activity may follow as more clinical data become available.
The stability of the toxin preparation over time is clearly critical to building up an effec tive clinical data base and we are able to con firm that our freeze-dried toxin retains stability even when kept at 4° C for not less than 3 years. Thus the potency of the prep aration is a constant factor even when used in different clinics, countries and over a long time period and should enable a consistent dose regime to be established for a range of dystonia conditions. As the data presented above show, not only is the mode and site of action of the toxin highly specific but it also possesses a further important characteristic which is its avidity for the site of action. Taken together these characteristics allow local injection into a muscle with little or no general dissemination. It will eventually be interesting to investigate the clinical use of the pure 150,000 MW neu rotoxin as this molecule which does not have the haem agglutinin moiety of the complex toxin may give even better precision and reproducibility of action.
Further development may be required if there is evidence of production of antibody by patients receiving toxin. Should this become a problem it would be necessary to make avail able other of the serologically distinct toxin Types B through G and the information currently being pursued on the structure and activity of these other toxins should prove invaluable in assessing their suitability for clinical use. Inv est Ophthalmol1973 , 12: 924-7. 
